GLP-1RAs: What are the future directions in development?
5 Things a cardiologist needs to know about GLP-1 RA
Subtitling in English, German, Italian, Spanish, French, and Chinese
5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.
Video navigation menu
- Obesity drives T2DM and CVD 00:35
- How do GLP-1RAs reduce CV risk? 03:13
- Strategies to prevent T2DM and CVD 06:21
- Barriers to use of GLP-1RAs 09:32
This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.
Prof. John Deanfield, Professor of Cardiology, University College London, United Kingdom.
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.